The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 801–900 of 1,002
Luo, C., Hou, M., Huang, C., Wu, C., Ou‐Yang, F., Li, Q.-L., Wu, C.-C., & Pan, M. (2020) · American Journal of Cancer Research · Cited by 21
Zheng, Z., Hong, D., Zhang, X., Chang, Y., Sun, N., Lin, Z., Li, H., Huang, S., Zhang, R., Xie, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673223 · Cited by 21
“However, the development of CDK inhibitors is challenging, and several clinical trials have shown disappointing results (10, 11).”
BackgroundWu, B., Yang, W., Fu, Z., Xie, H., Guo, Z., Liu, D., Ge, J., Zhong, S., Liu, L., Liu, J., et al. (2021) · Aging · doi:10.18632/aging.203165 · Cited by 21
“CDK1 is necessary for the proliferation of mammalian cells, and is the only CDK that can initiate mitosis (M phase) [7].”
BackgroundFatahala, S. S., Sayed, A. I., Mahgoub, S., Taha, H., El-Sayed, M.-I. K., Shehry, M. F. E., Awad, S. M., & El-Hameed, R. H. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111957 · Cited by 21
“The assay was done as formerly described, using Roscovitine as a reference standard [69].”
MethodJanáčová, L., Stenckova, M., Lapčík, P., Hrachovinová, Š., Bouchalová, P., Potěšil, D., Hrstka, R., Müller, P., & Bouchal, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-28078-1 · Cited by 21
A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?
Lang, P. Y., & Gershon, T. R. (2018) · BioEssays · doi:10.1002/bies.201700243 · Cited by 21
Kaku, Y., Tsuchiya, A., Kanno, T., & Nishizaki, T. (2015) · Pharmacology · doi:10.1159/000381029 · Cited by 20
Zhang, Y., Yin, F., Luo, Z., Zheng, Y., Guo, S., Wu, S., Jiang, Y., Zheng, L., Ma, L., Zou, M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01058 · Cited by 20
Wang, S., Bei, Y., Tian, Q., He, J., Wang, R., Wang, Q., Sun, L., Ke, J.-Q., Xie, C., & Shen, P. (2022) · Cell Proliferation · doi:10.1111/cpr.13337 · Cited by 21
“Given the finding that inhibiting CDK4 and CDK6 might retard cancer cell development, several CDK4/6 dual-inhibitors come into being and show both good preclinical and clinical outcomes.(9) Fortunately, several ATP-competitive inhibitors of CDK4/6 have been approved and utilized in clinical applications, including pal…”
BackgroundTherapeutic targets in cancer treatment: Cell cycle proteins
Selvaraj, C. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.003 · Cited by 20
Khan, S. U., Fatima, K., Singh, U., Singh, P. P., & Malik, F. A. (2023) · Medical Oncology · doi:10.1007/s12032-023-01963-5 · Cited by 20
Vigolo, M., Urech, C., Lamy, S., Monticone, G., Zabaleta, J., Hossain, F. M., Wyczechowska, D. D., Valle, L. D., O'Regan, R. M., Miele, L., et al. (2023) · Cancers · doi:10.3390/cancers15153957 · Cited by 20
“Selective CDK4/6 inhibitors (CDKis) [43] are FDA-approved in combination with endocrine therapy to treat patients in first- and second-line settings [29,30,44].”
BackgroundComing of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 21
“Given the critical role of cyclins/CDKs in cancer, cyclin/CDK-targeting therapies have been the focal point of cancer research for many years [12,15,16].”
CDK4/6 inhibitors: The Devil is in the Detail
Magge, T., Rajendran, S., Brufsky, A., & Foldi, J. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01540-7 · Cited by 20
“For example, abemaciclib is 14 times more potent at inhibiting CDK4 than CDK6 [19] and it has five-fold more potency for CDK4 than palbo-ciclib and ribociclib [18, 20].”
Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance
Xue, Y., & Zhai, J. (2024) · International Journal of Clinical and Experimental Pathology · doi:10.62347/hgni4903 · Cited by 20
Merritt, J. M., Andiappan, M., Pietz, M. A., Richey, R. N., Sullivan, K. A. M., & Kjell, D. P. (2015) · Organic Process Research & Development · doi:10.1021/acs.oprd.5b00324 · Cited by 20
Wang, Z., Sun, W., Wang, X., Zhang, Y., Qiu, H., Qi, J., Pang, Y., Lu, G., Wang, X., Yu, F., et al. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12942 · Cited by 20
Xu, Z., Zhou, Y., Shi, F., Cao, Y., Dinh, T. L. A., Wan, J., & Zhao, M. (2017) · Oncology Letters · doi:10.3892/ol.2017.5766 · Cited by 20
“As a protein kinase of the CDK family, CDK1 performed an important role in cell cycle progression (19).”
Jing, L., Tang, Y., Goto, M., Lee, K., & Xiao, Z. (2018) · RSC Advances · doi:10.1039/c8ra01440j · Cited by 20
Xie, G., Zhou, Y., Tu, X., Ye, X., Xu, L., Xiao, Z., Wang, Q., Wang, X., Du, M., Chen, Z., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.11.012 · Cited by 20
FRMD8 targets both CDK4 activation and RB degradation to suppress colon cancer growth
Yu, M., Wu, W., Sun, Y., Yan, H., Zhang, L., Wang, Z., Gong, Y., Wang, T., Li, Q., Song, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112886 · Cited by 21
Tetrahydro-3 H -pyrazolo[4,3- a ]phenanthridine-based CDK inhibitor
Opoku‐Temeng, C., Dayal, N., Hernandez, D. E., Naganna, N., & Sintim, H. O. (2018) · Chemical Communications · doi:10.1039/c8cc01154k · Cited by 20
Targeting Molecular Pathways in Intracranial Metastatic Disease
Venur, V. A., Cohen, J. V., & Brastianos, P. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00099 · Cited by 20
“The phosphorylation of tumor suppressor proteins like retinoblastoma protein is a key function of CDK4/6 which leads to cell division and proliferation (61).”
BackgroundBreakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Tsironis, G., Ziogas, D. C., Kyriazoglou, A., Lykka, M., Koutsoukos, K., Bamias, A., & Dimopoulos, M.-A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.18 · Cited by 19
Wu, T., Yang, Z., Chen, W., Jiang, M., Xiao, Z., Su, X., Jiao, Z., Yu, Y., Chen, S., Song, M., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01571-2 · Cited by 19
“As a result, FOXD1 resists cellular senescence and facilitates HNSCC cell proliferation by affecting the expression of the p21/ CDK2/Rb signaling pathway, suggesting that blockade of the FOXD1/p21/CDK2/Rb axis may be a potential treatment for HNSCC.”
BackgroundTomita, A., Sasanuma, H., Owa, T., Nakazawa, Y., Shimada, M., Fukuoka, T., Ogi, T., & Nakada, S. (2023) · Nature Communications · doi:10.1038/s41467-023-41048-5 · Cited by 19
“Palbociclib, a speci fi c CDK4 and CDK6 inhibitor 30 , arrested TK6261 cells in the G1 phase after 24 h of treatment.”
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
Huang, Y., Liu, W., Zhao, C., Shi, X., Zhao, Q., Jia, J., & Wang, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116547 · Cited by 19
Translating RB1 predictive value in clinical cancer therapy: Are we there yet?
Indovina, P., Pentimalli, F., Conti, D., & Giordano, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.003 · Cited by 19
CASC21, a FOXP1 induced long non-coding RNA, promotes colorectal cancer growth by regulating CDK6
Gong, T., Yu, L., Feng, L., Fang, M., Dai, G., Huang, X. Y., Yang, Y., & Liu, S. (2020) · Aging · doi:10.18632/aging.103376 · Cited by 19
“It can combine with cyclinD to form a complex and promote the release of E2F family transcription factors, thereby promoting cell proliferation [36, 37].”
BackgroundDinaciclib, a Bimodal Agent Effective against Endometrial Cancer
Howard, D., James, D. H., Murphy, K., García-Parra, J., Pan‐Castillo, B., Rex, S., Moul, A., Jones, E., Bilbao‐Asensio, M., Michue‐Seijas, S., et al. (2021) · Cancers · doi:10.3390/cancers13051135 · Cited by 19
“Early trials with panCDKis including flavopiridol and dinaciclib failed due to off-target effects limiting their therapeutic window and therefore efficacy [18].”
BackgroundSurien, O., Ghazali, A. R., & Masre, S. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-94508-7 · Cited by 19
Hsieh, M., Lin, C., Lo, Y., Chuang, Y., Ho, H., & Chen, M. (2021) · Cancers · doi:10.3390/cancers13174327 · Cited by 20
“The G2/M phase is one of the most prominent checkpoints in the cell cycle that is controlled by cyclin B/CDC2 [52].”
BackgroundShaikh, J., Patel, K. N., & Khan, T. A. (2021) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557521666211027104957 · Cited by 19
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
Naim, N., Moukheiber, S., Daou, S., & Kourié, H. R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103524 · Cited by 19
Iuliani, M., Simonetti, S., Ribelli, G., Napolitano, A., Longo, U. G., Vincenzi, B., Orsaria, P., Denaro, V., Tonini, G., Santini, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052477 · Cited by 19
Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
Zhu, L., Yang, Q., Hu, R., Li, Y., Peng, Y., Liu, H., Ye, M., Zhang, B., Zhang, P., Liu, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09592-0 · Cited by 19
Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management
Liang, X.-R., Liu, Y., Chen, F., Zhou, Z., Zhang, L., & Lin, Z. (2023) · Cancer Management and Research · doi:10.2147/cmar.s407371 · Cited by 19
“CDK4, CDK6 and CDK2 are often overexpressed and promotes cancer cell cycle progression, which in turn accelerates cell division and tumor growth.(54) Recent studies have shown that CDK expression could be regulated by certain lncRNAs and further affect tumorigenesis and progression (Table 2).”
BackgroundCell Cycle-Dependent Kinase Cdk9 Is a Postexposure Drug Target against Human Adenoviruses
Prasad, V. R., Suomalainen, M., Hemmi, S., & Greber, U. F. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00009 · Cited by 19
Jorda, R., Bučková, Z., Řezníčková, E., Bouchal, J., & Kryštof, V. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.11.011 · Cited by 19
Liu, S., Tang, Y., Yuan, X., Yuan, D., Liu, J., Li, B., & Li, Y. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0575-z · Cited by 19
“Cell cycle progression is frequently unbalanced in cancer and its inhibitors also attract plenty of attention for therapeutic application [1].”
BackgroundBevara, G. B., Kumar, A. D. N., Koteshwaramma, K. L., Badana, A. K., Kumari, S., & Malla, R. R. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_51_16 · Cited by 19
Heo, S., Noh, E., Gwon, G.-D., Kim, J. Y., Jo, J., Choi, Y., Koh, S., Baek, J. H., Min, Y. J., & Kim, H. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.07.049 · Cited by 19
El-wahab, H. A. A. A., Mansour, H. S., Ali, A. M., El‐Awady, R., & Aboul‐Fadl, T. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105622 · Cited by 18
Phosphorylated MED1 links transcription recycling and cancer growth
Chen, Z., Ye, Z., Soccio, R. E., Nakadai, T., Hankey, W., Zhao, Y., Huang, F., Yuan, F., Wang, H., Cui, Z., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac246 · Cited by 18
“As FP also inhibits several other CDKs in addition to CDK9 (45,46), we next asked whether FP inhibition of MED1 phosphorylation is mediated through CDK9.”
Lephatsi, M. M., Choene, M. S., Kappo, A. P., Madala, N. E., & Tugizimana, F. (2023) · Metabolites · doi:10.3390/metabo13101104 · Cited by 18
“…interacting with the different amino acid residues of CCNB1 and forming Cyclin-dependent kinases (CDKs) are a group of twenty serine/threonine kinases that have essential roles in governing cell proliferation, transcription, differentiation, and metabolism [78]. hydrogen bonds (Figure 7A).”
BackgroundSynergistic anticancer effect by targeting CDK2 and EGFR–ERK signaling
Wu, J., Chen, Y., Li, R., Guan, Y., Chen, M. H., Yin, H., Yang, X., Jin, M., Huang, B., Ding, X., et al. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202203005 · Cited by 18
“Cyclin-dependent kinases (CDKs), a large family of serine/ threonine protein kinases, play pivotal roles in regulating cell progression, cell cycle, survival, and proliferation (Asghar et al., 2015; Hochegger et al., 2008).”
Zaloa, W. A. Z. E., El‐Sayed, S. M., Alswah, M., El-morsy, A., Bayoumi, A. H., Mayhoub, A. S., Moustafa, W. H., Awaji, A. A., Roh, E. J., Hassan, A. H. E., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111593 · Cited by 18
“To con fi rm the inhibitory activity of the developed compounds on CDK2 as a mechanism of action involved in mediating cytotoxicity, the most e ff ective cytotoxic compounds, 4a and 4b , were employed in in vitro enzymatic CDK2 inhibition assays [36].”
MethodTranscriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Walker, R. L., Hornicek, F. J., & Duan, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116342 · Cited by 18
Huang, L. J., Guo, W., Zhao, T., Feng, Y., Li, Y., An, Q., Li, C., Tian, Y., Zhang, H., Zhou, C., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160172 · Cited by 18
Copper is essential for cyclin B1-mediated CDK1 activation
Wang, J., Yang, D., Yu, H., Jin, J., Nie, Y., Zhang, S., Ren, W., Ge, Z., Zhang, Z., Ma, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57538-7 · Cited by 18
“If duplicate simulations were performed as methods imply, RMSD and RMSF plots should have some indication of range to properly assess the significance of comparisons drawn between WT and the CBM.”
InfluentialMECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma
Pereira, S. S., Monteiro, M. P., Bourdeau, I., Lacroix, A., & Pignatelli, D. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0976 · Cited by 18
Function, Structure and Topology of Protein Kinases
Röhm, S., Krämer, A., & Knapp, S. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_97 · Cited by 18
Shukla, R., & Singh, T. R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1844050 · Cited by 18
“There are several enzymes involved in tau hyperphosphorylation in which the cyclin-dependent kinase 5 (CDK5) is a key enzyme for the regulation of tau phosphorylation (Asghar et al., 2015; Cruz & Tsai, 2004; Lai & Ip, 2015).”
BackgroundHe, F., Wang, X., Wu, Q., Liu, S.-Z., Cao, Y., Guo, X., Yin, S., Yin, N., Li, B., & Fang, M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106645 · Cited by 18
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 18
A patent review of selective CDK9 inhibitors in treating cancer
Wu, T., Wu, X., Xu, Y., Chen, R., Wang, J., Li, Z., & Bian, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2208747 · Cited by 18
“CDK9 inhibitors lack selectivity, leading to unpredictable side effects and termination of clinical trials of some panCDK9 inhibitors [13,14].”
BackgroundCell cycle gene expression networks discovered using systems biology: Significance in carcinogenesis
Scott, R. E., Ghule, P. N., Stein, J. L., & Stein, G. S. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24990 · Cited by 18
“Integration of regulatory activities that mediate cell cycle and cell growth control, as well as relate proliferation with competency for expression of phenotype, are fundamentally important for biological processes and cancer (Aguilar et al., 2014; Asghar et al., 2015; Datla et al., 2014; Dudakovic et al., 2014; Faul…”
BackgroundChen, Y., Qi, C., Xia, L., & Li, G. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4092 · Cited by 18
“Recent studies have established cell cycle kinases as anticancer drug targets by using Cdk4/6 inhibitors (27,28).”
Ansari, S. S., Sharma, A. K., Zepp, M., Ivanova, E., Bergmann, F., König, R., & Berger, M. R. (2017) · Oncotarget · doi:10.18632/oncotarget.23537 · Cited by 18
“Over the last two decades, numerous CDK inhibitors have been developed as cancer therapeutics [6] and various clinical trials in several tumor types have been carried out, reinforcing CDKs/cyclins as potential targets for anticancer drug development [7, 8].”
BackgroundCDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells
Ahmed, R. L., Shaughnessy, D. P., Knutson, T. P., Vogel, R. I., Ahmed, K., Kren, B. T., & Trembley, J. H. (2019) · Pharmaceuticals · doi:10.3390/ph12020050 · Cited by 18
“Aberrant expression or altered activity of distinct CDK complexes results in escape of cells from cell cycle control and plays a role in malignant transformation [6,7].”
BackgroundLong, Q., Ma, A., Zhang, H., Cao, Z., Xia, R., Lin, T., Sonpavde, G., White, R. D., Guo, J., & Pan, C.-X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02609-5 · Cited by 18
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
Julve, M., Clark, J. J., & Lythgoe, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1828348 · Cited by 18
“Advances in drug design and development allowed increased selectivity for CDK1 and CDK2, and a reduction in dose-limiting toxicities [44].”
BackgroundResultInfluentialHe, J., Zhao, X., Huang, C., Zhou, X., You, Y., Zhang, L., Lu, C., Yao, F., & Li, S. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480290 · Cited by 17
“CDK4 and the cyclin D1 complex are inhibited by INK4 proteins, which include p16, p17, p18, and p19 Under strong oncogenic stress, p16 overexpression ultimately regulates RB protein to suppress growth and cell cycle progression, which promotes oncogene-induced senescenc.(23,24) In certain pre-malignant lesions, high l…”
BackgroundRoggero, C. M., Ghosh, A. B., Devineni, A., Ma, S., Blatt, E. B., Raj, G. V., & Yin, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102231 · Cited by 17
Cell Cycle Dysregulation in Breast Cancer
Mir, M. A., Khan, S. U., & Aisha, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_5 · Cited by 17
El-Kalyoubi, S. A., El‐Sebaey, S. A., El‐Sayed, A. A., Abdelhamid, M. S., Agili, F., & Elfeky, S. M. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2232125 · Cited by 17
“The preparation of the target-designed compounds, pyrimidine Schiff bases 4 – 9 , and their selenium nanoforms 4NPs – 9NPs are outlined in Scheme 1 and Figure 3, respectively.”
InfluentialShen, J., Gong, X., Tan, S., Zhang, Y., Xia, R. M., Xu, S., Wang, S., Zhou, H., Jiang, Y., Zhao, T., et al. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673322212240620111356 · Cited by 17
Gong, C., Lin, Q., Qin, T., Zeng, Y., Xu, F., Yang, Y., Yin, D., Duan, Z., Chen, C.-L., Chow, L. W., et al. (2024) · Med · doi:10.1016/j.medj.2024.11.012 · Cited by 17
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Chen, W., Zhuang, X., Chen, Y., Yang, H., Shen, L., Feng, S., Min, W., Yuan, K., & Yang, P. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60846-6 · Cited by 17
Discovery of Dihydropyrrol-2-ones as Novel G0/G1-Phase Arresting Agents Inducing Apoptosis
Yang, D., Huang, C., Liao, H., Zhang, H., Wu, S., Zhu, Q., & Zhou, Z. (2019) · ACS Omega · doi:10.1021/acsomega.9b02543 · Cited by 17
Hsin, I., Chou, Y., Hung, W.-L., Ko, J., & Wang, P.-H. (2019) · Cancers · doi:10.3390/cancers12010108 · Cited by 17
“Mitotic signals stimulate CDK4 and CDK6 activities, which promote cancer cell proliferation through the entrance of G1 into the S phase in cell cycle [44].”
BackgroundLu, X., Zhan, R., Zhao, G., Qian, Z.-H., Gong, C., & Li, Y. (2020) · Journal of Investigative Surgery · doi:10.1080/08941939.2020.1852344 · Cited by 17
Miao, J., Meng, C., Wu, H., Shan, W., Wang, H., Ling, C., Zhang, J., & Yang, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.626065 · Cited by 17
Post-translational modifications of CDK5 and their biological roles in cancer
Gao, G., Sun, Y., Fang, R., Wang, Y., Wang, Y., & He, Q. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00029-0 · Cited by 17
Yuan, K., Kuang, W., Chen, W., Ji, M., Min, W., Zhu, Y., Hou, Y., Wang, X., Li, J., Wang, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114024 · Cited by 17
Anshabo, A. T., Mekonnen, L. B., Diab, S., Lenjisa, J. L., Kebede, A., Long, Y., Heinemann, G. K., Karanjia, J., Noll, B. D., Basnet, S. K. C., et al. (2022) · Cancers · doi:10.3390/cancers14051113 · Cited by 17
“, flavopiridol, dinaciclib) were non-selective and their clinical development is hindered due to off-target toxicities [28].”
BackgroundBarghi, F., Shannon, H. E., Saadatzadeh, M. R., Bailey, B. J., Riyahi, N., Bijangi‐Vishehsaraei, K., Just, M., Ferguson, M. J., Pandya, P. H., & Pollok, K. E. (2022) · Cancers · doi:10.3390/cancers14153611 · Cited by 17
“In the first gap phase (G1) of the cell cycle, the enzymatic activity of CDK4 and CDK6 are regulated positively by D-type cyclins (D1, D2, and D3), expressed in response to multiple extracellular signals such as stimulatory mitogens, cell–cell interaction, and differentiation inducers [86,87].”
BackgroundHoward, D., James, D. H., García-Parra, J., Pan‐Castillo, B., Worthington, J., Williams, N., Coombes, Z., Rees, S. C., Lutchman-Singh, K., Francis, L. W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1014280 · Cited by 18
“Numerous CDKis are currently undergoing clinical and preclinical evaluation for a range of cancers (14) with CDK4/6 specific inhibitors currently in use for hormone receptor-positive metastatic breast cancer (15, 16).”
BackgroundHuang, J., Tan, X., Liu, Y., Jiang, K., & Luo, J. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23518 · Cited by 17
“Restoring the function of nuclear cell cycle inhibitors is an effective strategy to significantly improve the sensitivity to chemotherapy.(58,59) Recent work indicates that cytoplasmic mislocalization”
BackgroundZhao, H., Hu, X., Cao, K., Zhang, Y., Zhao, K., Tang, C., & Feng, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.043 · Cited by 17
Ding, C., Wei, R., Rodríguez, R. A., & Mullor, M. D. M. R. (2019) · Europe PMC (PubMed Central) · Cited by 17
MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2
Liang, X.-H., Feng, Z., Liu, F.-Q., Yan, R., Yin, L., Shen, H., & Lu, H. (2020) · Cell Biology International · doi:10.1002/cbin.11442 · Cited by 17
Recabarren, R., Zinovjev, K., Tuñón, I., & Alzate‐Morales, J. H. (2020) · ACS Catalysis · doi:10.1021/acscatal.0c03304 · Cited by 17
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Yang, L., Chen, Y., Wang, N., & Han, W. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-21-36 · Cited by 16
“CDK4/cyclin D1 is associated with cell proliferation and is critical for maintaining the growth of breast cancer (21,22), while CDK6/cyclin D3 is associated with the hematopoietic system and is important for normal thymus development and the maturation of bone marrow hematopoietic stem cells (22).”
BackgroundIshaq, Y., Ikram, A., Alzahrani, B., & Khurshid, S. (2022) · Genes · doi:10.3390/genes14010013 · Cited by 16
Discovery of HyT‐Based Degraders of CDK9‐Cyclin T1 Complex
Lin, R., Yang, J., Liu, T., Wang, M., Ke, C., Luo, C., Lin, J. H., Li, J., & Lin, H. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300769 · Cited by 16
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
Ke, S., Dang, F., Wang, L., Chen, J.-Y., Naik, M. T., Li, W., Thavamani, A., Kim, N., Naik, N. M., Sui, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47427-w · Cited by 16
CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer
Wen, Y., Sun, X., Zeng, L., Liang, S., Li, D., Chen, X., Zeng, F., Zhang, C., Wang, Q., Zhong, Q., et al. (2024) · Advanced Science · doi:10.1002/advs.202400666 · Cited by 16
Csizmók, V., Grisdale, C. J., Williamson, L., Lim, H. J., Lee, L., Renouf, D. J., Jones, S. J. M., Marra, M. A., Laskin, J. J., & Smrke, A. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23259 · Cited by 16
Liu, Y., Deng, Y., Yang, C., & Naranmandura, H. (2024) · Bioengineering · doi:10.3390/bioengineering11111084 · Cited by 17
CDK4/6 inhibition in luminal breast cancer
Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0268-2 · Cited by 16
Microfluidic Cell Cycle Analysis of Spread Cells by DAPI Staining
Sun, J., Zhang, J., Yang, H., Wang, G., Li, Y., Zhang, X., Chen, Q., & Lang, M. (2017) · Micromachines · doi:10.3390/mi8020036 · Cited by 16
“inhibitors are more specific and have much lower IC50 as compared to other CDKs [3].”
BackgroundInfluentialAl-Shehri, M. M., Hefnawy, M., Abuelizz, H. A., & Alzamil, A. (2019) · Acta Chromatographica · doi:10.1556/1326.2019.00635 · Cited by 16
Identification of key candidate genes for colorectal cancer by bioinformatics analysis
Chen, Z., Lin, Y., Gao, J., Lin, S., Zheng, Y., Liu, Y., & Shao, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10996 · Cited by 16
“in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumori‐ genic events (45).”
BackgroundDown-regulation of CIT can inhibit the growth of human bladder cancer cells
Liu, Z., Yan, H., Yang, Y., Wei, L., Xia, S., & Xiu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109830 · Cited by 16
Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis
Li, L., Zhu, M., Hu, H., Wu, J., & Meng, D. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962135 · Cited by 16
“It has been recognized that CDK1 activity is dysregulated in tumorigenesis and is generally associated with a more aggressive cancer phenotype.(27) For thyroid cancer, it was reported that CDK1 inhibition could induce cell cycle arrest in the G2/M phase and also suppressed TC cell proliferation.”
BackgroundDecker, J. T., Kandagatla, P., Wan, L., Bernstein, R., Ma, J. A., Shea, L. D., & Jeruss, J. S. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1818518 · Cited by 16
Jansa, J., Jorda, R., Škerlová, J., Pachl, P., Peřina, M., Řezníčková, E., Heger, T., Gucký, T., Řezáčová, P., Lyčka, A., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113309 · Cited by 16
Zhou, J., Huang, R., 聂晚频, Yuan, J., Zhang, Z., Mi, L., & Wang, C. (2021) · Oncology Reports · doi:10.3892/or.2021.8042 · Cited by 16
Xu, G., Yan, X., Hu, Z., Zheng, L., Ding, K., Zhang, Y., Qing, Y., Liu, T., Cheng, L., & Shi, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671138 · Cited by 17
“CDK1 is the only CDK of critical importance in the process of cell proliferation, and the abnormal expression of CDK1 has been observed in a variety of primary cancers (Asghar et al., 2015).”
Background
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.